Novo Nordisk May Have Landed a Sweeter Deal in Medicare's GLP-1 Bridge Pilot
- Medicare's GLP-1 Bridge pilot, launched under the Trump administration, sets a flat $50 monthly co-pay for obesity drugs — including Novo Nordisk's Wegovy and Eli Lilly's Zepbound and orforglipron — for Part D beneficiaries from July 2026 to December 2027.
- STAT reporting suggests Novo Nordisk's negotiated terms under the pilot may be more advantageous than initially disclosed, potentially outperforming Lilly's arrangement.
💡 Points
A pricing edge over Lilly in this two-horse race is worth more than the headline $50 co-pay — share captured under a fixed-price pilot compounds fast, and better fine print (rebates, volume triggers) beats a flashier price point. Read this as both companies treating government-negotiated terms as a template to refine, not a one-off concession, ahead of oral GLP-1 competition.
Novo may be getting a better deal than expected with Medicare's Bridge program ↗